Overview

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
Phase:
Phase 2
Details
Lead Sponsor:
Aurinia Pharmaceuticals Inc.
Treatments:
Cyclosporine